(Q37842339)

24 August 2017

1 reference

title

Therapeutic potential of vaccines for Alzheimer's disease (English)

1 reference

24 August 2017

0 references

Salim Shah

1

1 reference

24 August 2017

Howard J Federoff

series ordinal

2

1 reference

24 August 2017

publication date

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

3

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

287-298

1 reference

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

24 August 2017

cites work

1 reference

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

Prevalence, incidence and duration of Braak's stages in the general population: can we know?

21 January 2018

1 reference

Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice

21 January 2018

1 reference

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

21 January 2018

1 reference

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

21 January 2018

1 reference

Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models

21 January 2018

1 reference

Convergence of amyloid-beta and tau pathologies on mitochondria in vivo

21 January 2018

1 reference

Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice

21 January 2018

1 reference

Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures.

21 January 2018

1 reference

Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease

21 January 2018

1 reference

Inflammatory markers and the risk of Alzheimer disease: the Framingham Study

21 January 2018

1 reference

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

21 January 2018

1 reference

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial

21 January 2018

1 reference

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

Purification and cloning of amyloid precursor protein beta-secretase from human brain

21 January 2018

1 reference

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease

21 January 2018

1 reference

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective

21 January 2018

1 reference

APP gene family. Alternative splicing generates functionally related isoforms

21 January 2018

1 reference

A portrait of Alzheimer secretases--new features and familiar faces

21 January 2018

1 reference

Regulation of APP cleavage by alpha-, beta- and gamma-secretases

21 January 2018

1 reference

The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus

21 January 2018

1 reference

Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease

21 January 2018

1 reference

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

21 January 2018

1 reference

21 January 2018

Amyloid-beta aggregation

1 reference

Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders

21 January 2018

1 reference

Aggregation State and Neurotoxic Properties of Alzheimer Beta-Amyloid Peptide

21 January 2018

1 reference

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

21 January 2018

1 reference

Spontaneous Aggregation and Cytotoxicity of the β-Amyloid Aβ1–40: A Kinetic Model

21 January 2018

1 reference

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

21 January 2018

1 reference

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

The significance of neuroinflammation in understanding Alzheimer's disease.

21 January 2018

1 reference

Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases.

21 January 2018

1 reference

ER calcium and Alzheimer's disease: in a state of flux

21 January 2018

1 reference

Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals

21 January 2018

1 reference

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal

21 January 2018

1 reference

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

21 January 2018

1 reference

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition

21 January 2018

1 reference

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

21 January 2018

1 reference

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease

21 January 2018

1 reference

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis

21 January 2018

1 reference

Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease

21 January 2018

1 reference

Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

21 January 2018

1 reference

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

21 January 2018

1 reference

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

21 January 2018

1 reference

Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch

21 January 2018

1 reference

Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants

21 January 2018

1 reference

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice

21 January 2018

1 reference

Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice

21 January 2018

1 reference

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing

21 January 2018

1 reference

Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease

21 January 2018

1 reference

DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

21 January 2018

1 reference

Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety

21 January 2018

1 reference

Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy

21 January 2018

1 reference

Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine.

21 January 2018

1 reference

Infectivity of herpes simplex virus type-1 (HSV-1) amplicon vectors in dendritic cells is determined by the helper virus strain used for packaging.

21 January 2018

1 reference

Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4.

21 January 2018

1 reference

HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.

21 January 2018

1 reference

Development of vaccination approaches for the treatment of neurological diseases

21 January 2018

1 reference

Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model

21 January 2018

1 reference

A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease

21 January 2018

1 reference

Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease

21 January 2018

1 reference

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

Cerebral hemorrhage after passive anti-Abeta immunotherapy

21 January 2018

1 reference

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

21 January 2018

1 reference

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody

21 January 2018

1 reference

Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo

21 January 2018

1 reference

21 January 2018

1 reference

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease

21 January 2018

1 reference

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

21 January 2018

1 reference

Natural human antibodies to amyloid beta peptide

21 January 2018

1 reference

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice

21 January 2018

1 reference

Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease

21 January 2018

1 reference

Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease

21 January 2018

1 reference

Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.

21 January 2018

1 reference

Neuroimaging through the course of Alzheimer's disease

21 January 2018

1 reference

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.10.94

1 reference

24 August 2017

1 reference